AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $253.78, giving the company a market capitalization of 449.03B. It carries a P/E multiple of 124.96 and pays a dividend yield of 2.66%.
As of 2026-06-29, AbbVie(ABBV) stock has fluctuated between $249.20 and $255.96. The current price stands at $253.78, placing the stock +1.8% above today's low and -0.9% off the high.
The AbbVie(ABBV)'s current trading volume is 9.3M, compared to an average daily volume of 11.81M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $255.96 and a 52-week low of $181.73.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $255.96 and a 52-week low of $181.73.
ABBV News
AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody,...
A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Key Points AbbVie has outperformed the market this year, but its valuation remains modest. The company recently announced the acquisition of Apogee Therapeuti...
AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the ap...
In June 2026, AbbVie reported a series of regulatory wins, including expanded pediatric indications for SKYRIZI and broader HCV use for MAVIRET in Europe, along...
JPMorgan Equity Premium Income ETF ( $JEPI ) has risen by 0.16% in the past week. It has experienced a 5-day net inflow of $78.3 million. This is due, in part,...
AbbVie ( (ABBV) ) has risen by 10.15%. Read on to learn why. TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with T...
Analysts are intrested in these 5 stocks: ( (BWXT) ), ( (ALT) ), ( (GPN) ), ( (ABBV) ) and ( (NKE) ). Here is a breakdown of their recent ratings and the ration...
Goldman Sachs analyst Asad Haider maintained a Hold rating on AbbVie on June 22 and set a price target of $244.00. TipRanks' Prime Week Sale - 70% Off Unlock po...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.